Anzeige
Mehr »
Donnerstag, 11.09.2025 - Börsentäglich über 12.000 News
BREAKING NEWS: CiTech unterzeichnet Exklusivvertrag mit Babcock - Ukraine-Deal katapultiert Aktie in neue Liga
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P9T4 | ISIN: US8112922005 | Ticker-Symbol: 135A
Tradegate
08.09.25 | 14:00
0,779 Euro
-12,77 % -0,114
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
SCYNEXIS INC Chart 1 Jahr
5-Tage-Chart
SCYNEXIS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,8700,91010.09.
0,8720,91510.09.

Aktuelle News zur SCYNEXIS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
04.09.SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)1
13.08.SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update147First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold, triggering a $10M milestone payment from GSK. An additional $20M milestone will be triggered upon the...
► Artikel lesen
13.08.SCYNEXIS INC - 10-Q, Quarterly Report5
26.06.SCYNEXIS INC - 8-K, Current Report2
SCYNEXIS Aktie jetzt für 0€ handeln
28.05.Scynexis says GSK on hook for $10M payment after phase 3 Brexafemme trial starts back up20
28.05.SCYNEXIS resumes Phase 3 antifungal study after FDA lift2
28.05.SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study445First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical holdResumption of dosing in this study triggers a $10M milestone payment from GSK plus an additional $20M milestone...
► Artikel lesen
15.05.SCYNEXIS GAAP EPS of -$0.11 beats by $0.08, revenue of $0.26M beats by $0.12M22
15.05.SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update174Ibrexafungerp clinical hold lifted by the FDA. SCYNEXIS working to resolve a disagreement with GSK involving the restart of the MARIO study. GSK remains committed to the commercialization of Brexafemme.Hansoh...
► Artikel lesen
15.05.SCYNEXIS INC - 10-Q, Quarterly Report1
12.03.SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update788The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in Q3 of 2025.Four presentations for SCY-247 were accepted...
► Artikel lesen
18.12.24SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections251JERSEY CITY, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant...
► Artikel lesen
06.11.24SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update205Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10 million development milestone payment to...
► Artikel lesen
13 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1